Schering Inventory Reductions Cause Drop In Intron, Temodar, Nasonex Sales
Executive Summary
Schering-Plough's poor first quarter results reflect inventory buildup issues beyond Rx Claritin
You may also be interested in...
Bristol Restates, But Reforms Continue; Q3 Charges Show Old Habits Die Hard
Bristol is taking steps to create a more open environment for internal communications as part of ongoing reforms to its financial controls
Schering misjudges Claritin inventory
Schering-Plough is reducing its fourth quarter earnings estimate by about $250 mil. (16-18 cents per share) because of "a more-rapid-than-anticipated decline in U.S. prescriptions for Claritin" following the OTC launch in December. Schering says it will not record any sales on shipments of Rx product to wholesalers until an actual prescription is dispensed...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011